Chronic myelogenous leukemia, driven by the tyrosine kinase gene fusion BCR–ABL1, stands out as the tumor with the most notable success in molecularly targeted therapeutics to date. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.